Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
101 hedge funds and large institutions have $754M invested in Genomic Health, Inc. in 2014 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 37 increasing their positions, 27 reducing their positions, and 30 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less capital invested
Capital invested by funds: $807M → $754M (-$53.4M)
16% less funds holding
Funds holding: 120 → 101 (-19)
53% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 30
78% less call options, than puts
Call options by funds: $2.1M | Put options by funds: $9.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$21.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.3M |
| 3 |
VAM
Visium Asset Management
New York
|
+$8.81M |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.34M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$5.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$27M |
| 2 |
TA
Teachers Advisors
New York
|
-$3.86M |
| 3 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
-$3.19M |
| 4 |
Goldman Sachs
New York
|
-$3M |
| 5 |
Morgan Stanley
New York
|
-$2.4M |
GHDX Hedge Fund Activity: Q1 2014 in Review
101 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q1 2014, worth a combined $754M — down 6.6% from $807M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of GHDX and 14 opened new positions — a net loss of 16 holders — while 27 trimmed existing stakes and 37 added.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $21.5M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $27M sold.
- 101 institutional investors held Genomic Health, Inc. (GHDX) as of Q1 2014, down from 120 in Q4 2013.
- Funds reported $754M of Genomic Health, Inc. stock for Q1 2014, down 6.6% quarter-over-quarter.
- 14 funds opened new Genomic Health, Inc. positions in Q1 2014 and 30 closed out, a net change of -16 holders.
- The largest Genomic Health, Inc. buyer in Q1 2014 was Camber Capital Management, an estimated $21.5M added.
- The largest Genomic Health, Inc. seller in Q1 2014 was Lord, Abbett & Co, an estimated $27M sold.
Based on aggregated 13F filings for Q1 2014.